Prognostic significance of additional cytogenetic abnormalities in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-α: A Cancer and Leukemia Group B study

  • Authors:
    • Sherif S. Farag
    • Amy S. Ruppert
    • Krzysztof Mrózek
    • Andrew J. Carroll
    • Mark J. Pettenati
    • Michelle M. Le Beau
    • Bercedis L. Peterson
    • Bayard L. Powell
    • Howard Ozer
    • Richard T. Silver
    • Richard A. Larson
    • Clara D. Bloomfield
  • View Affiliations

  • Published online on: July 1, 2004     https://doi.org/10.3892/ijo.25.1.143
  • Pages: 143-151
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Secondary cytogenetic abnormalities at diagnosis of Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) have been associated with an inferior outcome in reported series of largely chemotherapy-treated patients. To date, no study has specifically focused on the prognostic significance of secondary karyotypic abnormalities, detected at the time of diagnosis, in interferon (IFN)-α treated patients. We compared the outcome of 29 newly diagnosed Ph+ CML patients with additional abnormalities to that of 234 sole Ph+ patients, treated on CALGB protocols with IFN-α alone or together with IFN-γ or low-dose cytarabine. Complete and partial cytogenetic responses were achieved in 20 and 19% of sole Ph+ patients, compared to 23 and 18%, respectively, of patients with additional abnormalities (P=1.00). None of 4 patients with ‘high-risk’ secondary abnormalities [+8, +Ph and i(17)(q10)], for whom follow-up cytogenetic samples were available, achieved a cytogenetic response. With a median follow-up of 11.3 years, the median overall survival (OS) was 6.0 years for sole Ph+ patients compared to 7.5 years for patients with additional abnormalities (P=0.70), with corresponding 8-year OS of 36 and 38%, respectively. On multivariable analysis, only age (P<0.001) and white blood cell count (P=0.02) were associated with outcome. We conclude that, with the possible exception of +8, +Ph and i(17)(q10), additional chromosomal abnormalities at diagnosis are not associated with inferior outcome in Ph+ CML patients treated with IFN-α-based therapy.

Related Articles

Journal Cover

July 2004
Volume 25 Issue 1

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Farag SS, Ruppert AS, Mrózek K, Carroll AJ, Pettenati MJ, Le Beau MM, Peterson BL, Powell BL, Ozer H, Silver RT, Silver RT, et al: Prognostic significance of additional cytogenetic abnormalities in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-α: A Cancer and Leukemia Group B study. Int J Oncol 25: 143-151, 2004
APA
Farag, S.S., Ruppert, A.S., Mrózek, K., Carroll, A.J., Pettenati, M.J., Le Beau, M.M. ... Bloomfield, C.D. (2004). Prognostic significance of additional cytogenetic abnormalities in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-α: A Cancer and Leukemia Group B study. International Journal of Oncology, 25, 143-151. https://doi.org/10.3892/ijo.25.1.143
MLA
Farag, S. S., Ruppert, A. S., Mrózek, K., Carroll, A. J., Pettenati, M. J., Le Beau, M. M., Peterson, B. L., Powell, B. L., Ozer, H., Silver, R. T., Larson, R. A., Bloomfield, C. D."Prognostic significance of additional cytogenetic abnormalities in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-α: A Cancer and Leukemia Group B study". International Journal of Oncology 25.1 (2004): 143-151.
Chicago
Farag, S. S., Ruppert, A. S., Mrózek, K., Carroll, A. J., Pettenati, M. J., Le Beau, M. M., Peterson, B. L., Powell, B. L., Ozer, H., Silver, R. T., Larson, R. A., Bloomfield, C. D."Prognostic significance of additional cytogenetic abnormalities in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-α: A Cancer and Leukemia Group B study". International Journal of Oncology 25, no. 1 (2004): 143-151. https://doi.org/10.3892/ijo.25.1.143